Is CON a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Rate is carrying growth, not volume, with revenue (ttm) at ~$2.29B, up ~14% year over year. The bear case rests on visit volumes track hiring and employment: employer services work is generated by new hires, and workers' compensation claims are generated by people actually on job sites, so a labor market slowdown hits both lines at once and there is no offsetting counter-cyclical revenue. Analysts covering it are spread from $28.00 to $37.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Visit volumes track hiring and employment: employer services work is generated by new hires, and workers' compensation claims are generated by people actually on job sites, so a labor market slowdown hits both lines at once and there is no offsetting counter-cyclical revenue. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $28.00, -19.4% from the $34.74 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Rate is carrying growth, not volume. In the second quarter of 2026, revenue per visit rose ~4.6% to ~$152.67 while visits per day grew only ~2.6%, so pricing did most of the work. The most optimistic analyst target on CON is $37.00, +6.5% from the $34.74 price. That figure is only reachable if this thesis works close to its best case.

Visit volumes track hiring and employment: employer services work is generated by new hires, and workers' compensation claims are generated by people actually on job sites, so a labor market slowdown hits both lines at once and there is no offsetting counter-cyclical revenue. Reimbursement is set by state workers' compensation boards rather than negotiated, so a single large state trimming or freezing its fee schedule can remove growth that the company cannot recover operationally, and management has already flagged New York as less attractive than Texas, California, Florida, or Pennsylvania. Leverage near 3.0x net is manageable but leaves less room than a debt-free peer if volumes disappoint, and clinician wage inflation is a real cost pressure in a business that is mostly people and leases. The company also inherits litigation exposure from its Select Medical era, including consolidated data-breach class action claims tied to the Perry Johnson and Associates transcription incident. Finally, the stock has roughly doubled off its 52-week low and sits at the top of its range after the second quarter print, so a good deal of the improved execution is already reflected in the price. The most pessimistic published target is $28.00, -19.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Concentra is the largest US occupational health provider by location count, running employer-focused injury care and physical exams through centers and onsite clinics.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Rate is carrying growth, not volume) stalling in the reported numbers rather than in the narrative, the risk above (visit volumes track hiring and employment: employer services work is generated by new hires, and workers' compensation claims are generated by people actually on job sites, so a labor market slowdown hits both lines at once and there is no offsetting counter-cyclical revenue) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

CON is Concentra Group Holdings Parent, Inc., listed on the New York Stock Exchange. The ticker has changed hands historically, so it is worth confirming: this is the occupational health company that IPO'd in July 2024 and was fully spun off from Select Medical on November 25, 2024. It is not Con Edison, which trades as ED.

Two main streams. Workers' compensation payers reimburse Concentra for treating job-related injuries at rates set by state fee schedules, and employers pay directly for pre-placement physicals, DOT exams, and drug screening. A smaller third bucket covers Concentra Telemed, Concentra Pharmacy, and medical compliance administration. In the second quarter of 2026, the network handled about 56,400 visits per business day at roughly $152.67 of revenue per visit.

Mostly the latter with an acquisition overlay. Organic visit volume grew only ~2.6% in the second quarter of 2026, while revenue per visit rose ~4.6% and adjusted EBITDA rose ~22.5%. That profile fits a mature, high-share operator harvesting administered rate increases and operating leverage rather than a business expanding into new demand. Acquisitions like Nova and Pivot are what add units.